Cost-effectiveness of pregabalin: A UK perspective

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 4, 2007, Pages 327-333

  Johnston, Ann ^a   Hamandi, Khalid ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cost effectiveness; Epilepsy; Neuropathic pain; Pregabalin

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; ETIRACETAM; FLUOROFELBAMATE; GABAPENTIN; GANAXOLONE; HARKOSERIDE; HUPERZINE; JZP 4; LAMOTRIGINE; LIDOCAINE; OPIATE DERIVATIVE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TALAMPANEL; TIAGABINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; ZONISAMIDE;

ADD ON THERAPY; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ATAXIA; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; LONG TERM CARE; NEUROPATHIC PAIN; NONHUMAN; POSTHERPETIC NEURALGIA; PRESCRIPTION; QT PROLONGATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SIDE EFFECT; SOMNOLENCE; SUDDEN DEATH; TRANQUILIZING ACTIVITY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 34548398384     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.4.327     Document Type: Review

References (31)

1. Taylor CP. The biology and pharmacology of calcium channel a2-d proteins CNS Drug Rev. 10, 183-188 (2004).
2. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236 (2002).
3. 3H-norepinephrine release from rat neocortical slices Synapse 45, 171-190 (2002).
4. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133-141 (2003).
5. Bailer M, Johannessen Sl, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73, 1-52 (2007).
6. Leach JP. Pregabalin - a new treatment for partial epilepsy and neuropathic pain. ACNR4(6), 33-34 (2005).
7. French JA, Kugler AR, Robbins JL et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures Neurology 60, 1631-1637 (2003).
8. Arroyo S, Anhut H, Kugler AR et al. The Pregabalin 1009-011 International Study Group. Pregabalin add-on treatment: a randomised double-blind placebo-controlled dose-response study in adults with partial seizures, Epilepsia 45, 20-27 (2004).
9. Beydoun A, Uthman BM, Kugler AR et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64, 475-480 (2005).
10. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures a novel evaluation of flexible-dose and fixed dose-treatment in a double-blind, placebo-controlled study. Epilepsia 46(12), 1926-1936 (2005).
11. Sabatowski R, Galvez R, Cherry DA et al.; 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia results of a randomised, placebo-controlled clinical trial. Pain 109(1-2), 26-35 (2004).
12. Dworkin RH, Corbin AE, Young JP et al. Pregabalin for the treatment of postherpatic neuralgia a randomized, placebo-controlled trial. Neurology 60, 1274-1283 (2003).
13. Van Seventer R, Feister HA, Young JP et al. Efficacy and tolerability of twice daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia a 13-week, randomized trial. Curr. Med. Res Opin. 22(2), 375-384 (2006).
14. Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6(4), 253-260 (2005).
15. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63(11), 2104-2110 (2004).
16. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy. a double-blind, placebo-controlled trial. Pain 110(3), 628-638 (2004).
17. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of twice-daily pregabalin in the treament of patients with chronic neuropathic pain evaluated with a novel study design: a 12-week, randomised, double-blind, multicentre, placebo-controlled evaluation of flexible and fixed-close regimens of pregabalin. Pain 115(3), 254-263 (2005).
18. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions Nat. Med. 10(7), 685-692 (2004).
19. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160(3), 533-540 (2003).
20. Mula M, Pini S, Cassano GB. The role of enticonvulsant in anxiety disorders a critical review of the evidence. J. Clin. Psychopharmacol. 27(3), 263-272 (2007).
21. Tarride J, Gordon A, Monyserrat V-L, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia a Canadian perspective. Clin. Ther. 11, 1922-1934 (2006).
22. Sirvein JL, Fife TD, Wingerchuk DM, Drazkowski MD. Second-generation antiepileptic drugs impact on balance a meta-analysis Mayo Clin. Proc 82(1), 40-47 (2007).
23. Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia a cost-effectiveness analysis J. Pain 5, 396-404 (2007).
24. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst. Rev. CD005451 (2005).
25. Hachinski V. New antiepileptic drugs the cost of innovation. Arch. Neurol. 55(8), 1142 (1998).
26. Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice the case of antiepileptic drugs Neurology 49(2), 333-337 (1997).
27. Heaney D, Sander JW. The cost-effectiveness of carbamazepine in epilepsy. Expert Rev. Pharmacoeconomics Outcomes Res 6(1), 13-18 (2006).
28. Chadwick D. Do new antiepileptic drugs justify their expensive? Arch Neurol. 55, 1140-1142 (1998).
29. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy. an unblinded randomised controlled trial. Lancet 369(9566), 1000-1015 (2007).
30. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin. Emerg Drugs 12(1), 113-126 (2007).
31. Regional drug and Therapeutics Centre New Drug Evalution: Pregabalin for neuropathic pain. Regional drug and Therapeutics Centre, Newcastle Upon Tyne, UK, No. 66 (2004).